Ulcerative Colitis

The clinical study is evaluating an oral investigational drug to see if it reduces the signs and symptoms of moderately to severely active ulcerative colitis by blocking certain processes involved in the inflammation pathway.

18 - 75 years of age
Compensation Provided
About the Study
The study aims to assess an oral investigational drug's effectiveness in reducing signs and symptoms of moderately to severely active ulcerative colitis by targeting specific processes in the inflammation pathway. Additionally, the study examines any potential adverse events or safety concerns related to the investigational drug, which is taken once a day as one to three tablets.
What does the study involve?
This study involves a randomized, double-blinded, placebo-controlled trial, where participants are assigned either the investigational drug or a placebo without knowing which. Participation can last 12 to 64 weeks, with an option to continue the investigational drug after the initial 12 weeks. Current medications may be continued alongside the investigational drug, subject to evaluation by the study doctor. For more details, contact the study site.
Who can participate?
Those eligible to participate are individuals currently experiencing symptoms such as diarrhea (with or without blood), stool urgency, or stool incontinence. Additionally, they must have received a diagnosis of ulcerative colitis and be between the ages of 18 and 75.
Where is the study taking place?
The study is being conducted at our Hollywood and Weston offices.
Is compensation provided?

Apply for this study

Please enter your name, a valid phone number, and a valid email address where you can be contacted.

More clinical trials at Encore Medical Research